Roland Andersson - PAREXEL International Senior Vice President - Clinical Research Services

President

Mr. Roland Andersson, Ph.D., is Senior Vice President, Clinical Research Services of the Company. In this position, he is responsible for the management of the Companys Phase IIIII client relationships on a global basis, including strategic accounts and the Companys Biopharm Unit, and also oversees the Companys Japanese operations. From February 2011 to February 2014, Dr. Andersson served as Managing Director at Accenture, a consulting company. From April 2010 to February 2011, he was a Partner with Back Bay Life Science Advisors, a life sciences consulting firm. From August 2003 to April 2010 he served as Senior Managing Director at Leerink Swann LLC, an investment bank since 2014.
Age 52
Tenure 10 years
Phone781 487-9900
Webhttp://www.parexel.com
Andersson received a Masters in Science in Engineering and a Ph.D. in Management from Linköping Institute of Technology, Sweden.

PAREXEL International Management Efficiency

The company has return on total asset (ROA) of 0.0471 % which means that it generated a profit of $0.0471 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.15 %, meaning that it created $0.15 on every $100 dollars invested by stockholders. PAREXEL International's management efficiency ratios could be used to measure how well PAREXEL International manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 671.5 M in liabilities with Debt to Equity (D/E) ratio of 105.8, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PAREXEL International has a current ratio of 1.42, which is within standard range for the sector. Debt can assist PAREXEL International until it has trouble settling it off, either with new capital or with free cash flow. So, PAREXEL International's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PAREXEL International sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PAREXEL to invest in growth at high rates of return. When we think about PAREXEL International's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Alexander DouglasThe Coca Cola
54
Andrew ArchambaultKeurig Dr Pepper
51
Ceree EberlyThe Coca Cola
53
Bernhard GoepeltThe Coca Cola
55
Paul KornerArdelyx
50
Lisa ChangThe Coca Cola
52
Marcos QuintoThe Coca Cola
56
Mark RandazzaThe Coca Cola
58
Charles MathisScanSource
55
David ThomasKeurig Dr Pepper
55
Bryan ShawArdelyx
61
Luiz EdmondAnheuser Busch Inbev
49
Jan CrapsAnheuser Busch Inbev
47
Robert LongThe Coca Cola
61
Carlos LisboaAnheuser Busch Inbev
55
Javier SanjinesFomento Economico Mexicano
61
Jason WarnerAnheuser Busch Inbev
48
Jose OrnelasFomento Economico Mexicano
68
Reginal SeetoArdelyx
44
Jaxie AltKeurig Dr Pepper
44
Nathan KalumbuThe Coca Cola
50
PAREXEL International Corporationration, a biopharmaceutical services company, offer clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology solutions and services for pharmaceutical, biotechnology, and medical device industries worldwide. PAREXEL International Corp (PRXL) is traded on NASDAQ Exchange in USA and employs 18,600 people.

Management Performance

PAREXEL International Leadership Team

Elected by the shareholders, the PAREXEL International's board of directors comprises two types of representatives: PAREXEL International inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PAREXEL. The board's role is to monitor PAREXEL International's management team and ensure that shareholders' interests are well served. PAREXEL International's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PAREXEL International's outside directors are responsible for providing unbiased perspectives on the board's policies.
Michelle Graham, Chief Human Resource Officer, Senior Vice President
Ulf Schneider, Chief Administrative Officer, Senior Vice President
Thomas Senderovitz, Senior Vice President - Clinical Research Services
Dana Callow, Presiding Independent Director
Emma Reeve, Interim CFO, Corporate Vice President Controller
Josef Rickenbach, Founder, Chairman and CEO
Patrick Fortune, Independent Director
Eduard Holdener, Independent Director
Simon Harford, CFO, Senior Vice President
Joshua Schultz, Senior Vice President-Worldwide Head of PAREXEL Access
Gadi Saarony, Senior Vice President - Clinical Research Services
Ellen Zane, Director, Member of Compensation Committee, Member of HR Committee, CEO of Tufts Medical Center and President of Tufts Medical Center
Christian Dreger, Senior Vice President - Parexel Access and Parexel Consulting
Xavier Flinois, President - Perceptive Informatics
Douglas Batt, Sr. VP, General Counsel and Secretary
Sybrand Pretorius, Senior Vice President Chief Scientific Officer
Maykin Ho, Director
Richard Love, Independent Director
Ronald Aldridge, Sr. Director, Investor Relations
Mark Goldberg, President COO
Roland Andersson, Senior Vice President - Clinical Research Services
Christopher Lindop, Independent Director
Ingo Bank, CFO and Sr. VP
David Godwin, Senior Vice President-Global Business

PAREXEL Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PAREXEL International a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards PAREXEL International in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, PAREXEL International's short interest history, or implied volatility extrapolated from PAREXEL International options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as PAREXEL International using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.
You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Other Consideration for investing in PAREXEL Stock

If you are still planning to invest in PAREXEL International check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PAREXEL International's history and understand the potential risks before investing.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Global Correlations
Find global opportunities by holding instruments from different markets
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Stocks Directory
Find actively traded stocks across global markets